The Trump administration is ending a federal subsidy program that has helped stabilize Medicare prescription drug premiums, with the termination set for January 1, 2027. The approximately $9.8 billion Medicare Part D Premium Stabilization Demonstration will conclude a year ahead of its originally planned timeline, potentially affecting monthly costs for millions of beneficiaries.
The subsidy was created in response to the Inflation Reduction Act's 2022 provision capping Part D deductibles and shifting more costs to insurance companies. When insurers warned that coverage costs would increase in 2025, likely leading to higher premiums, CMS implemented the pilot program to help subsidize lower prices for consumers. The program mandated that insurance plans could not increase premiums by more than $35 between 2024 and 2025.
Medicare Part D itself is not ending under this change. Officials emphasize that beneficiaries will still have access to prescription drug coverage through the program, though individual plan costs may vary.
What the Right Is Saying
Republicans and administration officials say the change represents a return to normal market operations after a temporary subsidy program completed its original purpose. CMS Administrator Dr. Mehmet Oz has stated that most Medicare enrollees can expect to pay less than $10 more in monthly premiums, characterizing the impact as modest.
Conservative commentators have argued that the subsidy was always intended as a temporary measure and that its conclusion is appropriate given improved market stability in the Part D program. Supporters of the termination say ending government subsidies allows insurance markets to function more naturally without artificial price controls.
Some Republican lawmakers have noted that Medicare Part D itself remains fully funded and unchanged, with only the demonstration subsidy being discontinued. They argue this distinction matters for accurately describing what is happening to seniors' benefits.
What the Left Is Saying
Democratic lawmakers and healthcare advocates say the early termination of the subsidy places an unfair burden on seniors who can least afford higher costs. Senator Amy Klobuchar of Minnesota said the move prioritizes cutting government spending over protecting vulnerable Americans who depend on affordable medications.
Advocacy groups including AARP have expressed concern about the timing, noting that beneficiaries will face these changes during open enrollment season when many are already overwhelmed by plan selection decisions. Juliette Cubanski, vice president and director of KFF's Program on Medicare Policy, said this year's Annual Notice of Change letters warrant careful review because recipients need to examine premium adjustments closely.
Ann Bush, a 70-year-old from Missouri with Type 1 diabetes who relies on an insulin pump and takes medications following a kidney transplant three years ago, told PBS NewsHour she is worried about affording potential increases in premiums and co-pays. "Already I've had to decline medications from my doctor based on their affordability," Bush said.
Progressive groups argue that the termination could disproportionately affect beneficiaries with chronic conditions requiring expensive specialty medications, many of whom are already stretching limited budgets to cover healthcare costs.
What the Numbers Show
According to a federal government report cited by CMS, beneficiaries' premiums were approximately $26 lower in 2025 and about $16 lower in 2026 on average than they would have been without the subsidy program. The full impact of the termination on 2027 premiums has not yet been quantified.
CMS announced it will release additional key information about premium projections in September, ahead of the open enrollment period running from October 15 through December 7. Plan sponsors can begin marketing their offerings on October 1.
The Low-Income Subsidy program, known as Extra Help, remains available to individuals with income below $23,940 and married couples earning less than $32,460 annually. Qualifying beneficiaries pay no premiums, no deductibles, and no more than $12.65 for prescription drugs under this program.
Medicare Advantage plans were not part of the subsidy demonstration and will not be affected by its termination. Only standalone drug plans participated in the program.
The Bottom Line
The Medicare Part D Premium Stabilization Demonstration is ending January 1, 2027, approximately one year earlier than originally planned. While Part D coverage itself remains intact for all beneficiaries, individual plan premiums and cost-sharing structures may change when new offerings are announced during open enrollment this fall.
Beneficiaries should carefully review their Annual Notice of Change documents when they arrive, comparing available plans on Medicare.gov or through State Health Insurance Assistance Programs. The Extra Help program continues to provide comprehensive coverage at minimal cost for those who qualify based on income thresholds.
CMS is expected to release additional premium projection data in September, which will provide a clearer picture of potential cost changes heading into 2027.